Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01981954 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
A Phase 3 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT01981954 is a Phase 3 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 23 participants.
The verdict
NCT01981954, a Phase 3 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.
Interventions
- DRUG Solifenacin succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-09-25 |
| Est. Completion | 2015-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01981954
The ClinicalTrials.gov registry entry for NCT01981954 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Solifenacin succinate is the first listed.
NCT01981954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01981954 about?
NCT01981954 is a clinical study titled "A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)". The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.
What is the current status of trial NCT01981954?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2013-09-25. Estimated completion is 2015-12-18.
What interventions are being tested in trial NCT01981954?
The interventions under investigation include: Solifenacin succinate (DRUG).
Who is sponsoring clinical trial NCT01981954?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.